Journal of Taibah University Medical Sciences · 2025
Impact of CYP2A6 genetic polymorphism on letrozole efficacy in Iraqi women with polycystic ovary syndrome.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kareem Nawar R, Mosa Amal U, Rashid Al-Juhiashi Atheer M
Аннотация
OBJECTIVES: This study investigated the effects of a genetic polymorphism in CYP2A6 (CYP2A6∗2, 1799T>A) on the therapeutic response to letrozole in Iraqi women with polycystic ovarian syndrome (PCOS)-induced infertility.
METHODS: A prospective, single-center, randomized, controlled pragmatic clinical trial was conducted in 94 Iraqi women with PCOS-induced infertility. The ovulation response to letrozole (2.5 mg/day for 5 days) was assessed via ultrasound (follicle size ≥18 mm) and hormonal assays (follicle-stimulating hormone, luteinizing hormone, estradiol, prolactin, testosterone, and anti-Müllerian hormone). Genotyping of CYP2A6∗2 (1799T>A, rs1801272) was performed using allele-specific PCR on blood-derived DNA, and the distribution of wild-type (AA), heterozygous (AT), and mutant (TT) alleles was recorded. The association between genotype and letrozole efficacy, including follicle size, endometrial thickness, sex hormone levels, and pregnancy incidence, was also evaluated.
RESULTS: The wild-type allele (AA) of the CYP2A6∗2 gene (1799A>T, rs1801272) was widely distributed in approximately 51 (54.26 %) women with PCOS. Heterozygous alleles (AT) and mutant alleles (TT) were present in 2 (2.13 %) and 41 (43.61 %) women with PCOS, respectively. There was no notable difference between infertile women who did or did not respond to letrozole and those who carried different genotypes (wild-type AA, heterozygous AT, and mutant TT) of CYP2A6 (1799T>A) regarding sex hormones, follicle size, endometrial thickness, or incidence of gestation (P > 0.05).
CONCLUSION: The CYP2A62 (1799T>A) genetic variant was not associated with letrozole efficacy or resistance in Iraqi women with PCOS, suggesting that this polymorphism does not significantly influence therapeutic outcomes.
METHODS: A prospective, single-center, randomized, controlled pragmatic clinical trial was conducted in 94 Iraqi women with PCOS-induced infertility. The ovulation response to letrozole (2.5 mg/day for 5 days) was assessed via ultrasound (follicle size ≥18 mm) and hormonal assays (follicle-stimulating hormone, luteinizing hormone, estradiol, prolactin, testosterone, and anti-Müllerian hormone). Genotyping of CYP2A6∗2 (1799T>A, rs1801272) was performed using allele-specific PCR on blood-derived DNA, and the distribution of wild-type (AA), heterozygous (AT), and mutant (TT) alleles was recorded. The association between genotype and letrozole efficacy, including follicle size, endometrial thickness, sex hormone levels, and pregnancy incidence, was also evaluated.
RESULTS: The wild-type allele (AA) of the CYP2A6∗2 gene (1799A>T, rs1801272) was widely distributed in approximately 51 (54.26 %) women with PCOS. Heterozygous alleles (AT) and mutant alleles (TT) were present in 2 (2.13 %) and 41 (43.61 %) women with PCOS, respectively. There was no notable difference between infertile women who did or did not respond to letrozole and those who carried different genotypes (wild-type AA, heterozygous AT, and mutant TT) of CYP2A6 (1799T>A) regarding sex hormones, follicle size, endometrial thickness, or incidence of gestation (P > 0.05).
CONCLUSION: The CYP2A62 (1799T>A) genetic variant was not associated with letrozole efficacy or resistance in Iraqi women with PCOS, suggesting that this polymorphism does not significantly influence therapeutic outcomes.